Met Life Investment Management, LLC Syndax Pharmaceuticals Inc Transaction History

Met Life Investment Management, LLC

$17.1 Billion
Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 47,554 shares of SNDX stock, worth $622,006. This represents 0.01% of its overall portfolio holdings.

Number of Shares

47,554

Previous 47,554 -0.0%

Holding current value

$622,006

Previous $976,000 6.25%

% of portfolio

0.01%

Previous 0.01%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$18.82 - $23.79 $136,068 - $172,001	7,230 Added 17.93%	47,554 $976,000
Q1 2024 May 14, 2024	BUY	$19.71 - $24.57 $794,786 - $990,760	40,324 New	40,324 $959,000
Q3 2023 May 09, 2024	BUY	$14.52 - $21.77 $45,389 - $68,053	3,126 Added 9.88%	34,755 $504,000
Q2 2023 Apr 29, 2024	BUY	$19.35 - $22.31 $672,509 - $775,384	34,755 New	34,755 $727,000
Q2 2023 Aug 10, 2023	BUY	$19.35 - $22.31 $60,488 - $69,741	3,126 Added 9.88%	34,755 $727,000
Q1 2023 May 09, 2024	BUY	$20.66 - $28.98 $653,455 - $916,608	31,629 New	31,629 $668 Million
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $76,483 - $107,283	3,702 Added 13.26%	31,629 $668,000
Q4 2022 May 10, 2024	BUY	$20.64 - $26.24 $18,534 - $23,563	898 Added 3.32%	27,927 $710,000
Q4 2022 Jun 14, 2023	SELL	$20.64 - $26.24 $76,409 - $97,140	-3,702 Reduced 11.7%	27,927 $710,000
Q4 2022 Mar 22, 2023	BUY	$20.64 - $26.24 $18,534 - $23,563	898 Added 3.32%	27,927 $710,000
Q4 2022 Feb 15, 2023	BUY	$20.64 - $26.24 $18,534 - $23,563	898 Added 3.32%	27,927 $710,000
Q3 2022 Jun 14, 2023	SELL	$18.51 - $24.79 $85,146 - $114,034	-4,600 Reduced 14.54%	27,029 $649,000
Q2 2022 Jun 20, 2023	SELL	$13.64 - $19.48 $62,744 - $89,608	-4,600 Reduced 14.54%	27,029 $520,000
Q1 2022 May 10, 2024	BUY	$14.84 - $22.15 $401,110 - $598,692	27,029 New	27,029 $469,000
Q1 2022 Jun 20, 2023	SELL	$14.84 - $22.15 $68,264 - $101,890	-4,600 Reduced 14.54%	27,029 $469,000
Q1 2022 Mar 22, 2023	BUY	$14.84 - $22.15 $148,043 - $220,968	9,976 Added 58.5%	27,029 $469,000
Q1 2022 May 12, 2022	BUY	$14.84 - $22.15 $148,043 - $220,968	9,976 Added 58.5%	27,029 $470,000
Q4 2021 Jun 21, 2023	SELL	$15.23 - $22.47 $221,992 - $327,522	-14,576 Reduced 46.08%	17,053 $373,000
Q3 2021 Jun 21, 2023	SELL	$13.87 - $19.8 $202,169 - $288,604	-14,576 Reduced 46.08%	17,053 $325,000
Q2 2021 May 17, 2024	BUY	$13.42 - $25.18 $78,345 - $147,000	5,838 Added 52.06%	17,053 $292,000
Q2 2021 Jun 21, 2023	SELL	$13.42 - $25.18 $195,609 - $367,023	-14,576 Reduced 46.08%	17,053 $292,000
Q2 2021 Mar 22, 2023	BUY	$13.42 - $25.18 $78,345 - $147,000	5,838 Added 52.06%	17,053 $292,000
Q2 2021 Aug 16, 2021	BUY	$13.42 - $25.18 $78,345 - $147,000	5,838 Added 52.06%	17,053 $293,000
Q1 2021 May 17, 2024	SELL	$19.28 - $24.59 $561,221 - $715,790	-29,109 Reduced 72.19%	11,215 $250,000
Q1 2021 Jun 26, 2023	SELL	$19.28 - $24.59 $393,581 - $501,980	-20,414 Reduced 64.54%	11,215 $251 Million
Q4 2020 Jun 22, 2023	SELL	$15.1 - $26.44 $308,251 - $539,746	-20,414 Reduced 64.54%	11,215 $249,000
Q3 2020 Jun 26, 2023	SELL	$13.39 - $17.48 $273,343 - $356,836	-20,414 Reduced 64.54%	11,215 $165,000
Q2 2020 May 24, 2024	SELL	$8.94 - $20.98 $260,234 - $610,706	-29,109 Reduced 72.19%	11,215 $166 Million
Q2 2020 Jun 26, 2023	SELL	$8.94 - $20.98 $182,501 - $428,285	-20,414 Reduced 64.54%	11,215 $166,000
Q1 2020 Jul 12, 2023	SELL	$6.65 - $12.03 $135,753 - $245,580	-20,414 Reduced 64.54%	11,215 $123,000
Q1 2020 Mar 22, 2023	SELL	$6.65 - $12.03 $111,134 - $201,045	-16,712 Reduced 59.84%	11,215 $123,000
Q1 2020 May 15, 2020	BUY	$6.65 - $12.03 $74,579 - $134,916	11,215 New	11,215 $123,000

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account

Met Life Investment Management, LLC Syndax Pharmaceuticals Inc Transaction History